These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 12569155)

  • 1. HIV protease inhibitors and atherosclerosis.
    Hui DY
    J Clin Invest; 2003 Feb; 111(3):317-8. PubMed ID: 12569155
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages.
    Dressman J; Kincer J; Matveev SV; Guo L; Greenberg RN; Guerin T; Meade D; Li XA; Zhu W; Uittenbogaard A; Wilson ME; Smart EJ
    J Clin Invest; 2003 Feb; 111(3):389-97. PubMed ID: 12569165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV protease inhibitors-induced atherosclerosis: prevention by alpha-tocopherol.
    Munteanu A; Ricciarelli R; Zingg JM
    IUBMB Life; 2004 Oct; 56(10):629-31. PubMed ID: 15814462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.
    Wilson ME; Sengoku T; Allred KF
    J Cell Biochem; 2008 Apr; 103(5):1598-606. PubMed ID: 17879945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease.
    Zhou H; Pandak WM; Lyall V; Natarajan R; Hylemon PB
    Mol Pharmacol; 2005 Sep; 68(3):690-700. PubMed ID: 15976036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD36 overexpression in ritonavir-treated THP-1 cells is reversed by alpha-tocopherol.
    Munteanu A; Zingg JM; Ricciarelli R; Azzi A
    Free Radic Biol Med; 2005 Apr; 38(8):1047-56. PubMed ID: 15780763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stem cell transplantation reveals that absence of macrophage CD36 is protective against atherosclerosis.
    Febbraio M; Guy E; Silverstein RL
    Arterioscler Thromb Vasc Biol; 2004 Dec; 24(12):2333-8. PubMed ID: 15486305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-lactam compounds as apparently uncompetitive inhibitors of HIV-1 protease.
    Sperka T; Pitlik J; Bagossi P; Tözsér J
    Bioorg Med Chem Lett; 2005 Jun; 15(12):3086-90. PubMed ID: 15893929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV protease inhibitors increase TNF-alpha and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR.
    Zhou H; Jarujaron S; Gurley EC; Chen L; Ding H; Studer E; Pandak WM; Hu W; Zou T; Wang JY; Hylemon PB
    Atherosclerosis; 2007 Nov; 195(1):e134-43. PubMed ID: 17531241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How HIV protease inhibitors promote atherosclerotic lesion formation.
    Thomas CM; Smart EJ
    Curr Opin Lipidol; 2007 Oct; 18(5):561-5. PubMed ID: 17885428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV protease inhibitors.
    Winslow DL; Otto MJ
    AIDS; 1995; 9 Suppl A():S183-92. PubMed ID: 8819585
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal.
    Ishii T; Itoh K; Ruiz E; Leake DS; Unoki H; Yamamoto M; Mann GE
    Circ Res; 2004 Mar; 94(5):609-16. PubMed ID: 14752028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspartic proteases of Plasmodium falciparum as the target of HIV-1 protease inhibitors.
    Savarino A; Cauda R; Cassone A
    J Infect Dis; 2005 Apr; 191(8):1381-2; author reply 1382-3. PubMed ID: 15776390
    [No Abstract]   [Full Text] [Related]  

  • 14. Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
    Yang ZH; Bai XG; Zhou L; Wang JX; Liu HT; Wang YC
    Bioorg Med Chem Lett; 2015 May; 25(9):1880-3. PubMed ID: 25838144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-malaria interactions: don't forget the drugs.
    Andrews KT; Gatton ML; Skinner-Adams TS; McCarthy JS; Gardiner DL
    Science; 2007 Mar; 315(5820):1791; author reply 1791. PubMed ID: 17395812
    [No Abstract]   [Full Text] [Related]  

  • 16. Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice.
    Holmstock N; Annaert P; Augustijns P
    Drug Metab Dispos; 2012 Aug; 40(8):1473-7. PubMed ID: 22550269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validated predictive QSAR modeling of N-aryl-oxazolidinone-5-carboxamides for anti-HIV protease activity.
    Halder AK; Jha T
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6082-7. PubMed ID: 20832304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the issue of cross-resistance between protease inhibitors.
    Birch C
    AIDS; 1998 Apr; 12(6):680-1. PubMed ID: 9583615
    [No Abstract]   [Full Text] [Related]  

  • 19. Discovery of potent HIV-1 protease inhibitors incorporating sulfoximine functionality.
    Lu D; Vince R
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5614-9. PubMed ID: 17822899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [[HIV protease inhibitors. Development and overview] ].
    Schleifer KJ
    Pharm Unserer Zeit; 2000 Nov; 29(6):341-9. PubMed ID: 11199910
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.